Phil Nadeau
Stock Analyst at TD Cowen
(4.63)
# 847
Out of 4,339 analysts
787
Total ratings
49.9%
Success rate
11.4%
Average return
Main Sectors:
Stocks Rated by Phil Nadeau
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BMRN BioMarin Pharmaceutical | Maintained: Buy | $120 | $52.88 | +126.93% | 83 | May 21, 2026 | |
| BIIB Biogen | Maintained: Buy | $215 | $193.08 | +11.35% | 52 | May 14, 2026 | |
| CABA Cabaletta Bio | Maintained: Buy | n/a | $3.72 | - | 14 | May 14, 2026 | |
| IPSC Century Therapeutics | Maintained: Buy | n/a | $2.17 | - | 3 | May 13, 2026 | |
| KURA Kura Oncology | Maintained: Buy | n/a | $10.41 | - | 21 | May 12, 2026 | |
| MLTX MoonLake Immunotherapeutics | Maintained: Buy | n/a | $18.23 | - | 19 | May 11, 2026 | |
| AURA Aura Biosciences | Maintained: Buy | n/a | $7.61 | - | 13 | May 11, 2026 | |
| ELVN Enliven Therapeutics | Maintained: Buy | n/a | $42.53 | - | 16 | May 8, 2026 | |
| VYGR Voyager Therapeutics | Maintained: Buy | n/a | $3.83 | - | 40 | May 7, 2026 | |
| VIR Vir Biotechnology | Maintained: Buy | n/a | $9.38 | - | 20 | May 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $5.52 | - | 18 | May 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $26.17 | - | 2 | May 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $200 | $155.73 | +28.43% | 56 | May 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $525 | $435.93 | +20.43% | 85 | May 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $3.08 | - | 27 | May 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $130 | $89.82 | +44.73% | 35 | May 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $19.90 | - | 20 | Apr 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $20.35 | - | 6 | Apr 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $41.72 | - | 29 | Mar 18, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $9.61 | n/a | 18 | Mar 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.0002 | n/a | 27 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $27.64 | n/a | 31 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $7.75 | n/a | 4 | Mar 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $12.33 | n/a | 3 | Feb 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $80 → $75 | $133.73 | n/a | 44 | Feb 4, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $7.09 | n/a | 12 | Nov 9, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $2.12 | n/a | 7 | Aug 7, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | n/a | $3.00 | n/a | 6 | Feb 26, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | $385 | $634.62 | n/a | 40 | Feb 6, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $3.47 | n/a | 14 | Jan 17, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $2 → $16 | $0.0001 | n/a | 14 | Nov 2, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $205 | $335.94 | n/a | 1 | Jul 26, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $2.06 | n/a | 1 | May 3, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $185 | $578.43 | n/a | 5 | Apr 28, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $16.67 | n/a | 1 | Aug 7, 2015 |
BioMarin Pharmaceutical
May 21, 2026
Maintained: Buy
Price Target: $120
Current: $52.88
Upside: +126.93%
Biogen
May 14, 2026
Maintained: Buy
Price Target: $215
Current: $193.08
Upside: +11.35%
Cabaletta Bio
May 14, 2026
Maintained: Buy
Price Target: n/a
Current: $3.72
Upside: -
Century Therapeutics
May 13, 2026
Maintained: Buy
Price Target: n/a
Current: $2.17
Upside: -
Kura Oncology
May 12, 2026
Maintained: Buy
Price Target: n/a
Current: $10.41
Upside: -
MoonLake Immunotherapeutics
May 11, 2026
Maintained: Buy
Price Target: n/a
Current: $18.23
Upside: -
Aura Biosciences
May 11, 2026
Maintained: Buy
Price Target: n/a
Current: $7.61
Upside: -
Enliven Therapeutics
May 8, 2026
Maintained: Buy
Price Target: n/a
Current: $42.53
Upside: -
Voyager Therapeutics
May 7, 2026
Maintained: Buy
Price Target: n/a
Current: $3.83
Upside: -
Vir Biotechnology
May 7, 2026
Maintained: Buy
Price Target: n/a
Current: $9.38
Upside: -
May 7, 2026
Maintained: Buy
Price Target: n/a
Current: $5.52
Upside: -
May 7, 2026
Maintained: Buy
Price Target: n/a
Current: $26.17
Upside: -
May 5, 2026
Maintained: Buy
Price Target: $200
Current: $155.73
Upside: +28.43%
May 5, 2026
Maintained: Buy
Price Target: $525
Current: $435.93
Upside: +20.43%
May 5, 2026
Maintained: Buy
Price Target: n/a
Current: $3.08
Upside: -
May 5, 2026
Maintained: Buy
Price Target: $130
Current: $89.82
Upside: +44.73%
Apr 30, 2026
Maintained: Buy
Price Target: n/a
Current: $19.90
Upside: -
Apr 29, 2026
Maintained: Buy
Price Target: n/a
Current: $20.35
Upside: -
Mar 18, 2026
Maintained: Hold
Price Target: n/a
Current: $41.72
Upside: -
Mar 9, 2025
Maintained: Buy
Price Target: n/a
Current: $9.61
Upside: n/a
Nov 13, 2024
Rated: Hold
Price Target: n/a
Current: $0.0002
Upside: n/a
Oct 31, 2024
Maintained: Buy
Price Target: n/a
Current: $27.64
Upside: n/a
Mar 22, 2024
Rated: Hold
Price Target: n/a
Current: $7.75
Upside: n/a
Feb 13, 2023
Downgraded: Hold
Price Target: n/a
Current: $12.33
Upside: n/a
Feb 4, 2021
Maintained: Buy
Price Target: $80 → $75
Current: $133.73
Upside: n/a
Nov 9, 2020
Reiterated: Buy
Price Target: n/a
Current: $7.09
Upside: n/a
Aug 7, 2019
Maintained: Buy
Price Target: n/a
Current: $2.12
Upside: n/a
Feb 26, 2019
Initiated Coverage: Buy
Price Target: n/a
Current: $3.00
Upside: n/a
Feb 6, 2019
Rated: Hold
Price Target: $385
Current: $634.62
Upside: n/a
Jan 17, 2019
Maintained: Hold
Price Target: n/a
Current: $3.47
Upside: n/a
Nov 2, 2018
Maintained: Buy
Price Target: $2 → $16
Current: $0.0001
Upside: n/a
Jul 26, 2018
Rated: Buy
Price Target: $205
Current: $335.94
Upside: n/a
May 3, 2016
Reiterated: Hold
Price Target: n/a
Current: $2.06
Upside: n/a
Apr 28, 2016
Reiterated: Buy
Price Target: $185
Current: $578.43
Upside: n/a
Aug 7, 2015
Reiterated: Hold
Price Target: n/a
Current: $16.67
Upside: n/a